Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Other financing activities (2016 - 2025)

Historic Other financing activities for iBio (IBIO) over the last 15 years, with Q4 2025 value amounting to -$46.3 million.

  • iBio's Other financing activities changed N/A to -$46.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.7 million, marking a year-over-year increase of 441728.4%. This contributed to the annual value of $6.2 million for FY2025, which is 699772.73% up from last year.
  • Latest data reveals that iBio reported Other financing activities of -$46.3 million as of Q4 2025.
  • In the past 5 years, iBio's Other financing activities ranged from a high of $50.0 million in Q3 2025 and a low of -$46.3 million during Q4 2025
  • Over the past 5 years, iBio's median Other financing activities value was -$2500.0 (recorded in 2021), while the average stood at $372100.0.
  • As far as peak fluctuations go, iBio's Other financing activities plummeted by 28571.43% in 2023, and later soared by 28837.21% in 2024.
  • Over the past 5 years, iBio's Other financing activities (Quarter) stood at -$17000.0 in 2021, then dropped by 23.53% to -$21000.0 in 2022, then crashed by 285.71% to -$81000.0 in 2023, then surged by 200.0% to $81000.0 in 2024, then tumbled by 57318.52% to -$46.3 million in 2025.
  • Its Other financing activities stands at -$46.3 million for Q4 2025, versus $50.0 million for Q3 2025 and $81000.0 for Q2 2024.